Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors

Journal of Clinical Oncology

Volumn 28, Issue 31, 2010, Pages 4674-4682

  Ingle, James N ^a   Schaid, Daniel J ^a   Goss, Paul E ^a   Liu, Mohan ^a   Mushiroda, Taisei ^a   Chapman, Judy Anne W ^a   Kubo, Michiaki ^a   Jenkins, Gregory D ^a   Batzler, Anthony ^a   Shepherd, Lois ^a   Pater, Joseph ^a   Wang, Liewei ^a   Ellis, Matthew J ^a   Stearns, Vered ^a   Rohrer, Daniel C ^a   Goetz, Matthew P ^a   Pritchard, Kathleen I ^a   Flockhart, David A ^a   Nakamura, Yusuke ^a   Weinshilboum, Richard M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; EXEMESTANE; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 17 RECEPTOR A; UNCLASSIFIED DRUG; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; ESTROGEN; IL17RA PROTEIN, HUMAN; NITRILE; ONCOPROTEIN; TCL1A PROTEIN, HUMAN; TRIAZOLE DERIVATIVE;

ADULT; AGED; ARTHRALGIA; ARTHRITIS; ARTICLE; BONE PAIN; BREAST CANCER; CANCER GRADING; CHROMOSOME 14; CONTROLLED STUDY; DRUG WITHDRAWAL; ESTROGEN RESPONSIVE ELEMENT; FEMALE; GENE; GENE EXPRESSION; GENE LINKAGE DISEQUILIBRIUM; GENE MAPPING; GENETIC ASSOCIATION; GENOME; GENOTYPE; HUMAN; JOINT INJURY; MAJOR CLINICAL STUDY; MUSCULOSKELETAL DISEASE; MYALGIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; T CELL LEUKEMIA 1A GENE; BREAST TUMOR; CANCER STAGING; CASE CONTROL STUDY; CHROMOSOME MAP; COMPARATIVE STUDY; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HOSPITALIZATION; METABOLISM; MIDDLE AGED; MUSCULOSKELETAL SYSTEM; PATHOLOGY; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; STATISTICAL MODEL;

AGED; AGED, 80 AND OVER; ANDROSTADIENES; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 14; CLINICAL TRIALS, PHASE III AS TOPIC; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; LOGISTIC MODELS; MIDDLE AGED; MUSCULOSKELETAL SYSTEM; NEOPLASM STAGING; NITRILES; POLYMORPHISM, SINGLE NUCLEOTIDE; POSTMENOPAUSE; PROTO-ONCOGENE PROTEINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, INTERLEUKIN-17; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TRIAZOLES;

EID: 78149250018     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.28.5064     Document Type: Article

References (30)

1. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group, Forbes JF, Cuzick J, et al: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9:45-53, 2008
2. Coates AS, Keshaviah A, Thürlimann B, et al: Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98. J Clin Oncol 25:486-492, 2007 (Pubitemid 350002953)
3. Coombes RC, Kilburn LS, Snowdon CF, et al: Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): A randomised controlled trial. Lancet 369:559-570, 2007
4. Jakesz R, Jonat W, Gnant M, et al: Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366:455-462, 2005 (Pubitemid 41111693)
5. Boccardo F, Rubagotti A, Guglielmini P, et al: Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol 17:vii10-vii14, 2006 (suppl 7)
6. Kaufmann M, Jonat W, Hilfrich J, et al: Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: The ARNO 95 study. J Clin Oncol 25:2664-2670, 2007 (Pubitemid 47123171)
7. Goss PE, Ingle JN, Martino S, et al: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97:1262-1271, 2005 (Pubitemid 41535367)
8. Mamounas EP, Jeong JH, Wickerham DL, et al: Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: Intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial. J Clin Oncol 26:1965-1971, 2008
9. Winer EP, Hudis C, Burstein HJ, et al: American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004. J Clin Oncol 23:619-629, 2005
10. Partridge AH, LaFountain A, Mayer E, et al: Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 26:556-562, 2008 (Pubitemid 351264348)
11. Crew KD, Greenlee H, Capodice J, et al: Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 25:3877-3883, 2007 (Pubitemid 47477264)
12. Henry NL, Giles JT, Ang D, et al: Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat 111:365-372, 2008
13. Pearson TA, Manolio TA: How to interpret a genome-wide association study. JAMA 299:1335-1344, 2008
14. Solomon SD, McMurray JJ, Pfeffer MA, et al: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352:1071-1080, 2005 (Pubitemid 40365348)
15. Rosenbaum PR: Optimal matching for observational studies. J Am Stat Assoc 84:1024-1032, 1989
16. Patterson N, Price AL, Reich D: Population structure and eigenanalysis. PLoS Genet 2:e190, 2006
17. Price AL, Patterson NJ, Plenge RM, et al: Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 38:904-909, 2006 (Pubitemid 44141658)
18. Purcell S, Neale B, Todd-Brown K, et al: PLINK: A tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81:559-575, 2007 (Pubitemid 47330214)
19. Li Y, Willer CJ, Sanna S, et al: Genotype imputation. Annu Rev Genomics Hum Genet 10:387-406, 2009
20. Tian C, Gregersen PK, Seldin MF: Accounting for ancestry: Population substructure and genomewide association studies. Hum Mol Genet 17:R143-R150, 2008
21. Tian C, Plenge R, Ransom M, et al: Analysis and application of European genetic substructure using 300 K SNP information. PLoS Genetics 4:29-39, 2008
22. Yu K, Wang Z, Li Q, et al: Population substructure and control selection in genome-wide association studies. PLoS One 3:e2551, 2008
23. Devlin B, Roeder K. 1999. Genomic control for association studies. Biometrics 55:997-1004, 1999
24. Miossec P, Korn T, Kuchroo VK: Interleukin-17 and type 17 helper T cells. N Engl J Med 361:888-898, 2009
25. Kopec JA, Esdaile JM: Bias in case-control studies: A review. J Epidemiol Community Health 44:179-186, 1990
26. Manolio TA, Collins FS: The HapMap and genome-wide association studies in diagnosis and therapy. Annu Rev Med 60:443-456, 2009
27. Pekarsky Y, Hallas C, Croce CM: The role of TCL1 in human T-cell leukemia. Oncogene 20:5638-5643, 2001 (Pubitemid 32928103)
28. Noguchi M, Ropars V, Roumestand C, et al: Proto-oncogene TCL1: More than just a coactivator for Akt. FASEB J 21:2273-2284, 2007 (Pubitemid 47230657)
29. Cecil RL, Archer BH: Arthritis of the menopause. JAMA 84:75-79, 1925
30. Chlebowski RT, Johnson KC, Kooperberg C, et al: The Women's Health Initiative randomized trial of calcium plus vitamin D: Effects on breast cancer and arthralgias. J Clin Oncol 24:2s, 2006 (suppl; abstr LBA6).